Madison, Wisconsin - Post-menopausal women who had mild to moderate Alzheimer's disease and who wore a skin patch with natural estrogen for three months did better on cognitive tests than women who did not wear the patch, according to new findings by the
Medtronic, Inc., announced today that the U.S. Food and Drug Administration (FDA) has conditionally approved the protocol for SYMPLICITY HTN-3, the company's U.S. clinical trial of renal denervation with the Symplicity Catheter System for the treatment of
GlobalPost's "Global Pulse" blog features an interview with Ellen Starbird, deputy director of the Office of Population and Reproductive Health at USAID, and Judy Manning, health development officer in USAID's Research, Technology and Utilization Division